RESUMEN
Biotin (vitamin B7, or vitamin H) is a water-soluble B-vitamin that functions as a cofactor for carboxylases, i.e., enzymes involved in the cellular metabolism of fatty acids and amino acids and in gluconeogenesis; moreover, as reported, biotin may be involved in gene regulation. Biotin is not synthesized by human cells, but it is found in food and is also produced by intestinal bacteria. Biotin status/homeostasis in human individuals depends on several factors, including efficiency/deficiency of the enzymes involved in biotin recycling within the human organism (biotinidase, holocarboxylase synthetase), and/or effectiveness of intestinal uptake, which is mainly accomplished through the sodium-dependent multivitamin transporter. In the last years, administration of biotin at high/"pharmacological" doses has been proposed to treat specific defects/deficiencies and human disorders, exhibiting mainly neurological and/or dermatological symptoms and including biotinidase deficiency, holocarboxylase synthetase deficiency, and biotin-thiamine-responsive basal ganglia disease. On the other hand, according to warnings of the Food and Drug Administration, USA, high biotin levels can affect clinical biotin-(strept)avidin assays and thus lead to false results during quantification of critical biomarkers. In this review article, recent findings/advancements that may offer new insight in the abovementioned research fields concerning biotin will be presented and briefly discussed.
Asunto(s)
Biotina , Deficiencia de Biotinidasa , Biotinidasa , Homeostasis , Humanos , Biotina/metabolismo , Deficiencia de Biotinidasa/metabolismo , Deficiencia de Biotinidasa/diagnóstico , Deficiencia de Biotinidasa/genética , Deficiencia de Biotinidasa/tratamiento farmacológico , Biotinidasa/metabolismo , Biotinidasa/genética , Deficiencia de Holocarboxilasa Sintetasa/metabolismo , Ligasas de Carbono-Nitrógeno/metabolismo , Ligasas de Carbono-Nitrógeno/genética , Animales , Ataxia/metabolismo , Ataxia/genética , Enfermedades de los Ganglios BasalesRESUMEN
INTRODUCTION: Although the overall incidence of inborn errors of metabolism is low, their early diagnosis is essential, since some of them have a specific treatment. DEVELOPMENT: We review the main treatable inborn errors of metabolism that can present as early-onset epileptic encephalopathies, together with their biochemical markers and their treatment. CONCLUSIONS: It is important to think about the possibility of an inborn error of metabolism with a specific therapy, since it is crucial for this to be started as soon as possible in order to prevent permanent neurological damage.
TITLE: Abordaje metabolico en las encefalopatias epilepticas del lactante.Introduccion. Aunque la incidencia global de los errores congenitos del metabolismo es baja, su diagnostico precoz es fundamental, ya que algunos de ellos tienen tratamiento especifico. Desarrollo. Se revisan los principales errores congenitos del metabolismo tratables que pueden cursar como encefalopatia epileptica de inicio precoz, asi como sus marcadores bioquimicos y su tratamiento. Conclusiones. Es importante pensar en la posibilidad de un error congenito del metabolismo con terapia especifica, ya que es fundamental que esta comience lo antes posible para evitar un daño neurologico permanente.
Asunto(s)
Encefalopatías Metabólicas Innatas/metabolismo , Epilepsia/metabolismo , Edad de Inicio , Biotina/uso terapéutico , Encefalopatías Metabólicas/tratamiento farmacológico , Encefalopatías Metabólicas/metabolismo , Encefalopatías Metabólicas Innatas/tratamiento farmacológico , Encefalopatías Metabólicas Innatas/terapia , Preescolar , Creatina/metabolismo , Técnicas de Diagnóstico Neurológico , Epilepsia/tratamiento farmacológico , Enfermedades Fetales/genética , Enfermedades Fetales/metabolismo , Deficiencia de Holocarboxilasa Sintetasa/tratamiento farmacológico , Deficiencia de Holocarboxilasa Sintetasa/metabolismo , Humanos , Hipoxia-Isquemia Encefálica/tratamiento farmacológico , Hipoxia-Isquemia Encefálica/metabolismo , Lactante , Recién Nacido , Piridoxaminafosfato Oxidasa/deficiencia , Piridoxaminafosfato Oxidasa/metabolismo , Piridoxina/uso terapéutico , Convulsiones/tratamiento farmacológico , Convulsiones/metabolismoRESUMEN
Biotin (vitamins H and B7) is an important micronutrient as defects in its availability, metabolism or adsorption can cause serious illnesses, especially in the young. A key molecule in the biotin cycle is holocarboxylase synthetase (HLCS), which attaches biotin onto the biotin-dependent enzymes. Patients with congenital HLCS deficiency are prescribed oral biotin supplements that, in most cases, reverse the clinical symptoms. However, some patients respond poorly to biotin therapy and have an extremely poor long-term prognosis. Whilst a small number of mutations in the HLCS gene have been implicated, the molecular mechanisms that lead to the biotin-unresponsive phenotype are not understood. To improve our understanding of HLCS, limited proteolysis was performed together with yeast two-hybrid analysis. A structured domain within the N-terminal region that contained two missense mutations was identified in patients who were refractory to biotin therapy, namely p.L216R and p.L237P. Genetic studies demonstrated that the interaction between the enzyme and the protein substrate was disrupted by mutation. Further dissection of the binding mechanism using surface plasmon resonance demonstrated that the mutations reduced affinity for the substrate through a >15-fold increase in dissociation rate. Together, these data provide the first molecular explanation for HLCS-deficient patients that do not respond to biotin therapy.
Asunto(s)
Biotina/metabolismo , Deficiencia de Holocarboxilasa Sintetasa/metabolismo , Ligasas de Carbono-Nitrógeno/química , Ligasas de Carbono-Nitrógeno/aislamiento & purificación , Ligasas de Carbono-Nitrógeno/metabolismo , Deficiencia de Holocarboxilasa Sintetasa/genética , Humanos , Unión Proteica , Mapeo de Interacción de Proteínas , Piruvato Carboxilasa/metabolismo , Proteínas Recombinantes/química , Proteínas Recombinantes/aislamiento & purificación , Proteínas Recombinantes/metabolismoRESUMEN
We investigated in a patient with holocarboxylase synthetase deficiency, the relation between the biochemical and genetic factors of the mutant protein with the pharmacokinetic factors of successful biotin treatment. A girl exhibited abnormal skin at birth, and developed in the first days of life neonatal respiratory distress syndrome and metabolic abnormalities diagnostic of multiple carboxylase deficiency. Enzyme assays showed low carboxylase activities. Fibroblast analysis showed poor incorporation of biotin into the carboxylases, and low transfer of biotin by the holocarboxylase synthetase enzyme. Kinetic studies identified an increased Km but a preserved Vmax. Mutation analysis showed the child to be a compound heterozygote for a new nonsense mutation Q379X and for a novel missense mutation Y663H. This mutation affects a conserved amino acid, which is located the most 3' of all recorded missense mutations thus far described, and extends the region of functional biotin interaction. Treatment with biotin 100mg/day gradually improved the biochemical abnormalities in blood and in cerebrospinal fluid (CSF), corrected the carboxylase enzyme activities, and provided clinical stability and a normal neurodevelopmental outcome. Plasma concentrations of biotin were increased to more than 500 nM, thus exceeding the increased Km of the mutant enzyme. At these pharmacological concentrations, the CSF biotin concentration was half the concentration in blood. Measuring these pharmacokinetic variables can aid in optimizing treatment, as individual tailoring of dosing to the needs of the mutation may be required.
Asunto(s)
Biotina/administración & dosificación , Ligasas de Carbono-Nitrógeno/deficiencia , Deficiencia de Holocarboxilasa Sintetasa/tratamiento farmacológico , Secuencia de Aminoácidos , Biotina/metabolismo , Ligasas de Carbono-Nitrógeno/química , Ligasas de Carbono-Nitrógeno/genética , Células Cultivadas , Femenino , Deficiencia de Holocarboxilasa Sintetasa/genética , Deficiencia de Holocarboxilasa Sintetasa/metabolismo , Humanos , Recién Nacido , Cinética , Datos de Secuencia Molecular , Mutación , Alineación de SecuenciaRESUMEN
Multiple carboxylase deficiency is a clinical condition caused by defects in the enzymes involved in biotin metabolism, holocarboxylase synthetase (HLCS) or biotinidase. HLCS deficiency is a potentially fatal condition if left untreated, although the majority of patients respond to oral supplementation of 10-20 mg/day of biotin. Patients who display incomplete responsiveness to this therapy have a poor long-term prognosis. Here we investigated cell lines from two such HLCS-deficient patients homozygous for the c.647T>G p.L216R allele. Growth of the patients' fibroblasts was compromised compared with normal fibroblasts. Also the patient cells were not sensitive to biotin-depletion from the media, and growth rates could not be restored by re-administration of biotin. The molecular basis for the HLCS deficiency was further investigated by characterisation of the p.L216R protein. The HLCS mRNA was detected in MCD and normal cell lines. However, protein and enzyme activity could not be detected in the patients' cells. In vitro kinetic analysis revealed that enzyme activity was severely compromised for recombinantly expressed p.L216R and could not be increased by additional biotin. Furthermore, the turn-over rate for the mutant protein was double that of wildtype HLCS. These results help provide a molecular explanation for the incomplete biotin-responsiveness of this p.L216R form of HLCS.
Asunto(s)
Ligasas de Carbono-Nitrógeno/genética , Deficiencia de Holocarboxilasa Sintetasa/genética , Biotina/metabolismo , Ligasas de Carbono-Nitrógeno/metabolismo , Células Cultivadas , Femenino , Fibroblastos/metabolismo , Semivida , Deficiencia de Holocarboxilasa Sintetasa/metabolismo , Humanos , Recién Nacido , Masculino , Linaje , SamoaRESUMEN
The role of biotin as cofactor of carboxylases and its importance in metabolic homeostasis are well known. In recent years, different researchers have suggested the participation of biotin as a regulator molecule in the control of gene expression. Biotin-dependent gene expression requires of the transformation of biotin into biotinyl-5'-AMP by holocarboxylase synthetase and the activation of soluble guanylate cyclase and a cGMP-dependent protein kinase. The regulatory role of biotin is responsible for the correct expression of enzymes involved in biotin utilization in human cells. We propose that this mechanism protects the brain from biotin deficiency.
Asunto(s)
Biotina/metabolismo , Regulación de la Expresión Génica , Biotina/deficiencia , Deficiencia de Biotinidasa/metabolismo , Ligasas de Carbono-Nitrógeno/genética , Ligasas de Carbono-Nitrógeno/metabolismo , Deficiencia de Holocarboxilasa Sintetasa/metabolismo , Humanos , Simportadores/genética , Simportadores/metabolismoRESUMEN
Holocarboxylase synthetase (HCS) catalyzes the biotinylation of five carboxylases in human cells, and mutations of HCS cause multiple carboxylase deficiency (MCD). Although HCS also participates in the regulation of its own mRNA levels, the relevance of this mechanism to normal metabolism or to the MCD phenotype is not known. In this study, we show that mRNA levels of enzymes involved in biotin utilization, including HCS, are down-regulated during biotin deficiency in liver while remaining constitutively expressed in brain. We propose that this mechanism of regulation is aimed at sparing the essential function of biotin in the brain at the expense of organs such as liver and kidney during biotin deprivation. In MCD, it is possible that some of the manifestations of the disease may be associated with down-regulation of biotin utilization in liver because of the impaired activity of HCS and that high dose biotin therapy may in part be important to overcoming the adverse regulatory impact in such organs.